生物制药公司Anavex Life Sciences Corp.(AVXL)今日盘中大涨7.18%,引发市场关注。
消息面上,AVXL周一宣布,欧盟监管机构已正式受理其阿尔茨海默病候选药物blarcamesine的上市申请。这意味着blarcamesine有望成为目前全球首款口服治疗早期阿尔茨海默病的药物。
值得一提的是,blarcamesine作为新型口服治疗药物,与现有单克隆抗体等注射药的作用机理不同,可为阿尔茨海默病患者提供补充或替代选择。这为AVXL未来在巨大的阿尔茨海默病市场抢占一席之地带来了希望,从而推升公司股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.